Darren G Haskett1, Kamiel S Saleh2, Katherine L Lorentz3, Alexander D Josowitz2, Samuel K Luketich4, Justin S Weinbaum5, Lauren E Kokai6, Antonio D'Amore7, Kacey G Marra8, J Peter Rubin8, William R Wagner9, David A Vorp10. 1. Department of Surgery, University of Pittsburgh, Pittsburgh, Pa; Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa. 2. Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa. 3. Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa. 4. Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa; Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, Pa. 5. Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa; Department of Pathology, University of Pittsburgh, Pittsburgh, Pa. 6. McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa; Department of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pa. 7. Department of Surgery, University of Pittsburgh, Pittsburgh, Pa; Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa; Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, Pa; RiMED Foundation, Palermo, Italy. 8. Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa; Department of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pa. 9. Department of Surgery, University of Pittsburgh, Pittsburgh, Pa; Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa; Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, Pa; Center for Vascular Remodeling and Regeneration, University of Pittsburgh, Pittsburgh, Pa. 10. Department of Surgery, University of Pittsburgh, Pittsburgh, Pa; Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pa; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pa; Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, Pa; Center for Vascular Remodeling and Regeneration, University of Pittsburgh, Pittsburgh, Pa; Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pa. Electronic address: vorp@pitt.edu.
Abstract
OBJECTIVE: Tissue-engineered vascular grafts containing adipose-derived mesenchymal stem cells offer an alternative to small-diameter vascular grafts currently used in cardiac and lower-extremity revascularization procedures. Adipose-derived, mesenchymal stem cell-infused, tissue-engineered vascular grafts have been shown to promote remodeling and vascular homeostasis in vivo and offer a possible treatment solution for those with cardiovascular disease. Unfortunately, the time needed to cultivate adipose-derived mesenchymal stem cells remains a large hurdle for tissue-engineered vascular grafts as a treatment option. The purpose of this study was to determine if stromal vascular fraction (known to contain progenitor cells) seeded tissue-engineered vascular grafts would remain patent in vivo and remodel, allowing for a "same-day" process for tissue-engineered vascular graft fabrication and implantation. METHODS: Stromal vascular fraction, obtained from adult human adipose tissue, was seeded within 4 hours after acquisition from the patient onto poly(ester urethane)urea bilayered scaffolds using a customized rotational vacuum seeding device. Constructs were then surgically implanted as abdominal aortic interposition grafts in Lewis rats. RESULTS: Findings revealed patency in 5 of 7 implanted scaffolds at 8 weeks, along with neotissue formation and remodeling occurring in patent tissue-engineered vascular grafts. Patency was documented using angiography and gross inspection, and remodeling and vascular components were detected using immunofluorescent chemistry. CONCLUSIONS: A "same-day" cell-seeded, tissue-engineered vascular graft can remain patent after implantation in vivo, with neotissue formation and remodeling occurring by 8 weeks. Published by Elsevier Inc.
OBJECTIVE: Tissue-engineered vascular grafts containing adipose-derived mesenchymal stem cells offer an alternative to small-diameter vascular grafts currently used in cardiac and lower-extremity revascularization procedures. Adipose-derived, mesenchymal stem cell-infused, tissue-engineered vascular grafts have been shown to promote remodeling and vascular homeostasis in vivo and offer a possible treatment solution for those with cardiovascular disease. Unfortunately, the time needed to cultivate adipose-derived mesenchymal stem cells remains a large hurdle for tissue-engineered vascular grafts as a treatment option. The purpose of this study was to determine if stromal vascular fraction (known to contain progenitor cells) seeded tissue-engineered vascular grafts would remain patent in vivo and remodel, allowing for a "same-day" process for tissue-engineered vascular graft fabrication and implantation. METHODS: Stromal vascular fraction, obtained from adult human adipose tissue, was seeded within 4 hours after acquisition from the patient onto poly(ester urethane)urea bilayered scaffolds using a customized rotational vacuum seeding device. Constructs were then surgically implanted as abdominal aortic interposition grafts in Lewis rats. RESULTS: Findings revealed patency in 5 of 7 implanted scaffolds at 8 weeks, along with neotissue formation and remodeling occurring in patent tissue-engineered vascular grafts. Patency was documented using angiography and gross inspection, and remodeling and vascular components were detected using immunofluorescent chemistry. CONCLUSIONS: A "same-day" cell-seeded, tissue-engineered vascular graft can remain patent after implantation in vivo, with neotissue formation and remodeling occurring by 8 weeks. Published by Elsevier Inc.
Authors: Lorenzo Soletti; Alejandro Nieponice; Yi Hong; Sang-Ho Ye; John J Stankus; William R Wagner; David A Vorp Journal: J Biomed Mater Res A Date: 2010-12-09 Impact factor: 4.396
Authors: Lorenzo Soletti; Alejandro Nieponice; Jianjun Guan; John J Stankus; William R Wagner; David A Vorp Journal: Biomaterials Date: 2006-06-12 Impact factor: 12.479
Authors: Joydeep Basu; Christopher W Genheimer; Kelly I Guthrie; Namrata Sangha; Sarah F Quinlan; Andrew T Bruce; Bethany Reavis; Craig Halberstadt; Roger M Ilagan; John W Ludlow Journal: Tissue Eng Part C Methods Date: 2011-05-19 Impact factor: 3.056
Authors: Narutoshi Hibino; Tai Yi; Daniel R Duncan; Animesh Rathore; Ethan Dean; Yuji Naito; Alan Dardik; Themis Kyriakides; Joseph Madri; Jordan S Pober; Toshiharu Shinoka; Christopher K Breuer Journal: FASEB J Date: 2011-08-24 Impact factor: 5.191
Authors: Jeffrey T Krawiec; Justin S Weinbaum; Claudette M St Croix; Julie A Phillippi; Simon C Watkins; J Peter Rubin; David A Vorp Journal: Tissue Eng Part A Date: 2014-09-16 Impact factor: 3.845
Authors: Alejandro Nieponice; Lorenzo Soletti; Jianjun Guan; Yi Hong; Burhan Gharaibeh; Timothy M Maul; Johnny Huard; William R Wagner; David A Vorp Journal: Tissue Eng Part A Date: 2010-04 Impact factor: 3.845
Authors: Aneesh K Ramaswamy; Rachel E Sides; Eoghan M Cunnane; Katherine L Lorentz; Leila M Reines; David A Vorp; Justin S Weinbaum Journal: Matrix Biol Plus Date: 2019-09-04
Authors: Prerak Gupta; Katherine L Lorentz; Darren G Haskett; Eoghan M Cunnane; Aneesh K Ramaswamy; Justin S Weinbaum; David A Vorp; Biman B Mandal Journal: Acta Biomater Date: 2020-01-17 Impact factor: 10.633
Authors: Eoghan M Cunnane; Katherine L Lorentz; Lorenzo Soletti; Aneesh K Ramaswamy; Timothy K Chung; Darren G Haskett; Samuel K Luketich; Edith Tzeng; Antonio D'Amore; William R Wagner; Justin S Weinbaum; David A Vorp Journal: Front Bioeng Biotechnol Date: 2020-10-23